Description
Background:
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-A monoclonal antibody that binds multiple forms of A, such as soluble, oligomeric and fibrillar, for use in Alzheimer’s disease research. It clears excess A while exerting reduced subsequent effector function on microglia – desgined to stimulate amyloid phagocytosis while limiting release of inflammatory cytokines as a way to avoid side effects such as vasogenic edema.
Intended Use:
For Estimation of Crenezumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Crenezumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Crenezumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Crenezumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Crenezumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!